PTPN22 and neoplasm: Hence, the MMP-responsive DPPA-1 and LyP-1 peptide-modified Au@Pt NP (Au@Pt-LMDP)-treated group showed significant tumor inhibition with 100% survival after treatment (Yang et al., 2019b).